Don’t Buy Canopy Growth (TSX:WEED) Stock: These Pot Stocks Take the Cake

The market loves the partnership between Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Constellation Brands, Inc. (NYSE:STZ), but there are better cannabis stocks to trust with your money.

edit Jars of marijuana

Image source: Getty Images

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is one of the most loved cannabis stocks on the market. With a valuation of $8.6 billion, it’s also one of the largest.

One of the biggest reasons for Canopy’s vaunted position is Constellation Brands, Inc. (NYSE:STZ).

Constellation is a highly successful consumer brand company. With the rights to globally recognized brands like Modelo and Corona, Constellation is the largest beer importer in the U.S., generating more than $8 billion in annual sales.

Last year, Constellation invested more than $4 billion into Canopy, forming an exclusive partnership. With the influence, expertise, and financial backing of Constellation, the market fell in love with Canopy. At one point, it had a $20 billion market cap.

The Canopy-Constellation partnership is powerful, but that doesn’t make it the best place to put your money. In fact, if you want to bet on the benefits of that partnership, there are two superior options in which to invest.

Go bigger

If you want to invest in a cannabis stock because it has a high-powered partner, there’s no better option than Cronos Group Inc (TSX:CRON)(NYSE:CRON).

Pot is a highly regulated market. Navigating these regulations is extraordinarily difficult, especially if you want to be a global player. Every country has different rules.

In the U.S., the largest marijuana market in the world, regulations vary by state, and even by city.

When it comes to navigating complex, ever-evolving regulatory environments, Altria Group Inc (NYSE:MO) takes the cake. This $100 billion tobacco behemoth has proven an ability to dominate the market for controlled substances. If you invested in Altria stock back in 1979, you would have made 2,000 times your original investment.

This year, Altria took a $1.8 billion position in Cronos. Now Cronos can leverage the influence, connections, expertise, and financial backing of one of the most powerful tobacco companies on the planet. There really isn’t a more valuable partner to have.

Go wider

Hexo Corp. (TSX:HEXO)(NYSE:HEXO) realizes the value of a powerful partner, which is why it’s taking a different approach — one that will allow it to secure dozens of valuable partners.

Rather than simply growing pot and selling it on the open market or investing heavily to build its own cannabis brands, HEXO is partnering with existing companies to co-create products.

For example, it has a deal with Molson Coors Canada Inc. that will launch a cannabis-infused beverage in Canada this month.

Ask yourself which one is more likely to succeed: a Molson-branded beverage or a new beverage from an unknown start-up?

HEXO is betting that partnering with existing brands will give it immediate sales traction and customer loyalty. Its cannabis infrastructure is purposefully set up so that any company can co-create products alongside HEXO.

In 2020, expect the company to add new partners in emerging verticals like cosmetics and sleep aids, although consumables will still represent a big opportunity.

Investing in the Canopy-Constellation partnership bets that cannabis beverages will be a huge market. Why not invest in HEXO, then, which is capable of attracting dozens of simultaneous beverage partners?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands, HEXO., and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »